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INTRODUCTION
In October 2000, the Centers for Disease Control and
Prevention (CDC), the Infectious Diseases Society of Amer-
ica, and the American Society for Blood and Marrow Trans-
plantation issued guidelines on the prevention of opportunistic
infections in hematopoietic stem cell transplant (HSCT)
recipients [1]. The guidelines include evidence-based recom-
mendations rated by the strength of the recommendation
(Table 1) and the quality of the supporting evidence (Table 2).
This rating system is based on that created by the Infectious
Diseases Society of America and the United States Public
Health Service for guidelines on the prevention of opportunis-
tic infections in those with human immunodeﬁciency virus [2].
The HSCT guidelines apply to any transplantation of
blood- or marrow-derived hematopoietic stem cells, regard-
less of transplant type (ie, allogeneic or autologous) or cell
source (ie, bone marrow, peripheral blood, or placental or
umbilical cord blood), and they cover infections caused by
many pathogens. The recommendations relating speciﬁcally
to prevention of community-acquired respiratory virus
(CRV) infections are reviewed here.
PREVENTION OF EXPOSURE 
The most important step in the prevention of CRV dis-
ease among HSCT recipients is limiting their exposure to
persons infected with CRVs. The guidelines include the fol-
lowing recommendations to prevent such exposure [1]: 
• Health care workers and visitors with upper respiratory
tract infection (URTI) symptoms should be restricted
from contact with HSCT recipients and with HSCT can-
didates undergoing conditioning therapy (rating: AIII). 
• HSCT recipients and candidates, their family members
and visitors, and all health care workers should be educated
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regarding the importance of following CRV control meas-
ures and the potential severity of CRV infection among
HSCT recipients (rating: BIII).
• Even when no nosocomial or community outbreak of
CRV infections exists, all persons who enter the HSCT
center should be screened daily for URTI symptoms,
including visitors and health care workers (rating BIII).
Some centers place a stop sign at the entrance to remind
visitors and health care workers to stop for URTI screen-
ing before seeing patients. Other centers use a sign-in
sheet for staff members (see Nichols, this supplement). 
• Visitors with URTI symptoms should be asked to defer
their visit to the HSCT center until their symptoms
resolve (rating: BIII).
• Health care workers with URTI symptoms should be
restricted from patient contact and reassigned to non–
patient care duties until symptoms resolve (rating: BIII).
PREVENTION OF NOSOCOMIAL TRANSMISSION
Among the guidelines’ recommendations to prevent noso-
comial transmission of CRV infection are the following [1]:
• Physicians should institute appropriate precautions and
infection control measures for preventing nosocomial pneu-
monia among hospitalized HSCT recipients and candidates
undergoing conditioning therapy, particularly during com-
munity or nosocomial CRV outbreaks (rating: AIII).
• When determining the duration of appropriate precau-
tions for CRV-infected HSCT recipients or candidates
undergoing conditioning therapy, health care workers
should recognize that prolonged CRV shedding can occur
(rating: CIII). Viral shedding among HSCT recipients
with CRV infection has been reported to last up to
4 months for inﬂuenza, up to 2 years for adenovirus, and
up to 20 days for RSV (although longer durations for
RSV shedding among immunocompromised patients have
been reported (see Englund, this supplement).
• Active clinical surveillance for CRV disease should be
conducted on all hospitalized HSCT recipients and can-
didates undergoing conditioning therapy. This surveil-
lance should include daily checking for signs and symptoms
of CRV infection (rating: AIII). Viral cultures of speci-
mens from asymptomatic candidates for HSCT candi-
dates should not be done, however, because they are
unlikely to be useful.
• In outpatient waiting rooms, patients with CRV infec-
tions should be separated from other patients as much as
possible (rating: BIII).
• HSCT recipients with URTI or lower respiratory tract
infection (LRTI) symptoms should be placed under contact
precautions to avoid transmitting infection to other HSCT
candidates and recipients, health care workers, and visitors
until the cause of the infection is identiﬁed (rating: BIII).
• Optimal isolation precautions should be modified as
needed once the cause of the infection is identified
(rating: AIII). 
PREVENTION OF DISEASE
• HSCT physicians should determine the cause of a URTI,
if possible, because such infections can progress to more
serious LRTIs, and certain CRV infections can be treated
(rating: BIII).
• HSCT candidates with URTI symptoms at the time con-
ditioning therapy is scheduled to start should postpone
their conditioning regimen until the URTI is resolved, if
possible, because certain URTIs may progress to LRTIs
during immunosuppression (rating: BIII).
Table 1. Evidence-Based Rating System Used to Determine Strength of Recommendations of the HSCT Guidelines*
Category Definition Recommendation
A Both strong evidence for efficacy and substantial clinical benefit support Should always be offered 
recommendation for use
B Moderate evidence for efficacy—or strong evidence for efficacy, but Pros and cons should be discussed, but should 
only limited clinical benefit—supports recommendation for use generally be offered 
C Evidence for efficacy is insufficient to support a recommendation for Optional 
or against use, or evidence for efficacy may not outweigh the 
toxicity, drug interactions, or cost of chemoprophylaxis or
alternative approaches
D Moderate evidence for lack of efficacy or for adverse outcome Should generally not be offered 
supports a recommendation against use
E Good evidence for lack of efficacy or for adverse outcome supports Should never be offered 
a recommendation against use
*Adapted from [1]. 
Table 2. 
Evidence-Based Rating System Used to Determine Quality of Supporting
Evidence for Recommendations of the HSCT Guidelines*
Category Definition
I Evidence from at least 1 properly randomized, 
controlled trial
II Evidence from at least 1 well-designed clinical trial 
without randomization, from cohort or case-controlled 
analytic studies (preferably from more than 1 center), 
or from multiple time-series or dramatic results from 
uncontrolled experiments
III Evidence from opinions of respected authorities based on 
clinical experience, descriptive studies, or reports of 
expert committees
*Adapted from [1].
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PREVENTION OF RSV INFECTION
General
RSV is the most important CRV because it is the most
prevalent and because RSV pneumonia has a very high case-
fatality rate [3-6]. The following recommendations have
been made for prevention of RSV transmission [1]:
• Respiratory secretions of any hospitalized HSCT candi-
date or recipient who experiences signs or symptoms of
CRV infection should be tested promptly by viral culture
and rapid diagnostic tests for RSV (rating: BIII). 
• During RSV season, HSCT recipients and candidates
with signs or symptoms should be tested for RSV infec-
tion, as indicated by the presence of RSV antigen in respi-
ratory secretions tested by enzyme-linked immunosorbent
assay and viral culture, at admission to the HSCT center
and regularly thereafter. All patients who are RSV-antigen
positive should be treated as a cohort during nosocomial
RSV outbreaks, because this practice reduces nosocomial
RSV transmission (rating: BII).
• In a hospitalized HSCT candidate or recipient with
symptoms of respiratory infection, if 2 diagnostic samples
taken >2 days apart do not identify a respiratory pathogen
despite persistence of symptoms, a bronchoalveolar lavage
(BAL) specimen should be obtained for further testing
(rating: BIII). 
• HSCT recipients, particularly those who are preengraft-
ment and at highest risk for severe RSV pneumonia,
should have RSV infection diagnosed early (during RSV
URTI) and treated aggressively to prevent fatal RSV dis-
ease (rating: BIII).
• Although a definitive, uniformly effective preemptive
therapy for RSV infection among HSCT recipients has
not been identified, certain strategies have been pro-
posed, including the use of aerosolized ribavirin,
aerosolized ribavirin in combination with RSV antibod-
ies (high–RSV titer immunoglobulin or RSV immuno-
globulin), and RSV monoclonal antibody. No recom-
mendation regarding the optimal method of RSV
prevention and preemptive therapy can be made because
of limited data. 
Pediatric Patients
Among the recommendations for the prevention of RSV
infections in pediatric (<18 years old) HSCT recipients are
the following [1]:
• To prevent RSV disease in pediatric patients, some
experts suggest substituting RSV immunoglobulin for
standard immunoglobulin during the RSV season (Novem-
ber through April) in children who receive routine
immunoglobulin therapy (rating: CIII) (Table 3).
• Other researchers report that pediatric HSCT recipients
with RSV infection can be considered for preemptive
therapy (during URTI or early LRTI) with aerosolized
ribavirin (rating: CIII) (Table 3). This therapy remains
controversial. 
PREVENTION OF INFLUENZA VIRUS INFECTION
During the 1991-1992 inﬂuenza epidemic in Houston,
Texas, documented inﬂuenza virus infection was the cause of
acute URTI among 8 (29%) of 28 HSCT inpatients at M.D.
Anderson Cancer Center [7]. URTI was present on admis-
sion in 3 patients and was acquired in the hospital by the
other 5; mean time to acquisition was 20 days (range, 11-32
days). In 6 (75%) of the 8 infected patients, URTI pro-
gressed to pneumonia, and 1 patient died [7]. 
The guidelines make a number of recommendations for
the prevention of inﬂuenza, including the following [1]:
• Influenza vaccination of family members and close or
household contacts is strongly recommended during each
influenza season (October to May), starting the season
before HSCT and continuing ≥24 months after HSCT
(rating: AI).
• All family members and close or household contacts of
HSCT recipients who remain immunocompromised for
≥24 months after HSCT should continue annual
influenza vaccination as long as the HSCT recipient
remains immunocompromised (rating: AI).
• Seasonal inﬂuenza vaccination is strongly recommended
for all health care workers who care for HSCT recipients
(rating: AI). 
Table 3. Preventive Regimens for Pediatric HSCT Recipients With RSV Infection*
Indication First Choice Alternatives
Prophylaxis for RSV LRTI among patients RSV-IVIG† can be given in place of standard IVIG during RSV season None 
with hypogammaglobulinemia for those on routine IVIG therapy (rating: CIII) 
Usual RSV-IVIG dosage is 750 mg/kg per mo or a 1-mg/1-mg dosing 
substitution of RSV-IVIG for IVIG can be used in those who 
normally need high IVIG doses to keep serum IgG >400 mg/dL; 
can give more often than monthly as needed to keep serum IgG 
>400 mg/dL
Preemptive treatment of RSV URTI or Aerosolized ribavirin, 6 g/300 mL sterile water to make concentration 
early LRTI of 20 mg/mL; give 18 h/d for 10 d in a tent (rating: CIII)
For those with LRTI who cannot tolerate a tent or have RSV URTI, give
ribavirin as 2 g for 2 h every 8 h by face mask for 10 d, using SPAG-2
*Adapted from [1]. IgG indicates immunoglobulin G; IVIG, intravenous immunoglobulin; SPAG, small particle aerosol generator.
†RSV-IVIG is contraindicated among patients with IgA deﬁciency or who might have allergic reactions or anaphylaxis when receiving blood
products containing IgA (DIII). RSV monoclonal antibody is under investigational use among HSCT recipients for treatment with ribavirin but not
for prophylaxis.
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• If health care workers, family members, or close contacts
of HSCT recipients receive inﬂuenza vaccination during
an inﬂuenza A outbreak, they should receive amantadine
or rimantadine chemoprophylaxis for 2 weeks after
immunization (rating: BI).
• If a nosocomial outbreak is caused by an influenza A
strain not included in the current influenza vaccine, all
healthy family members, close and household contacts,
and health care workers caring for HSCT recipients and
candidates should be given inﬂuenza A chemoprophylaxis
with amantadine or rimantadine until the end of the out-
break (rating: BIII). 
• Health care workers, family members, or other close con-
tacts of HSCT recipients may be offered a neuraminidase
inhibitor (zanamivir or oseltamivir) if rimantadine or aman-
tadine cannot be tolerated, if the inﬂuenza outbreak is caused
by a strain of inﬂuenza A resistant to amantadine or rimanta-
dine, or if the outbreak strain is inﬂuenza B (rating: BI). 
• Lifelong seasonal inﬂuenza vaccination is recommended
for all HSCT candidates and recipients, beginning during
the influenza season before HSCT and resuming
≥6 months after HSCT (rating: BIII). This vaccination
schedule differs from the European recommendation,
which advises inﬂuenza vaccination for all HSCT recipi-
ents for only 2 years after transplantation.
• HSCT recipients <6 months after transplantation should
receive chemoprophylaxis with amantadine or rimanta-
dine during community or nosocomial influenza A out-
breaks (rating: BIII). These drugs are not effective against
influenza B. In addition, antiviral-resistant strains of
inﬂuenza can emerge during treatment with amantadine
or rimantadine and can be transmitted to others.
CONCLUSIONS
These evidence-based guidelines for preventing CRVs
among HSCT recipients, extracted from the complete
guidelines for preventing all opportunistic infections among
these patients, provide preventive strategies for HSCT recip-
ients, their household and close contacts, and their health
care workers. CRVs, which are generally manageable in
healthy immunocompetent individuals, can be difficult to
treat and even fatal in HSCT recipients. Therefore, prevent-
ing CRVs in this population is preferable to treating them.
Adherence to these guidelines should help reduce both the
number and the severity of CRVs in HSCT recipients.
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